Comparison of availability and accessibility of Immuno-oncology (IO) drugs for cancer treatment among Japan, Korea, China and Taiwan

被引：0
|
作者：
Lo, Joanne [1 ,2 ]
机构：
[1] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Sch Pharm, Coll Med, Tainan, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
280
引用
收藏
页码：139 / 139
页数：1
相关论文
共 11 条
  • [1] DIFFERENTIAL UPTAKE OF IMMUNO-ONCOLOGY (IO) TREATMENTS AMONG DIFFERENT INCOME LEVELS FOR NON-SMALL CELL CANCER PATIENTS IN CHINA
    De Richter, P.
    [J]. VALUE IN HEALTH, 2020, 23 : S66 - S66
  • [2] Integration of immuno-oncology (IO) treatments into routine clinical practice for the treatment of patients with advanced or metastatic cancers: Analysis of the England national cancer registry
    Mahmoudpour, Hamid
    Knott, Craig
    Amin, Amerah
    Boutmy, Emmanuelle
    Verpillat, Patrice
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 121 - 121
  • [3] Comparison of atmospheric mercury (Hg) among Korea, Japan, China and Taiwan during 2000-2008
    Fang, Guor-Cheng
    Wu, Yuh-Shen
    Chang, Tai-Hua
    [J]. JOURNAL OF HAZARDOUS MATERIALS, 2009, 162 (2-3) : 607 - 615
  • [4] Comparison of progression free survival (PFS) of patients with lung cancer treated with immuno-oncology (IO) drugs under real-world-conditions in oncological practices with published data of related pivotal studies
    Lipp, R.
    Eisen, A.
    Brecht, P.
    Schmitz, S.
    Tamimi, O.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 256 - 256
  • [5] SYSTEMATIC LITERATURE REVIEW FOR TREATMENT OUTCOMES (INCLUDING IMMUNO-ONCOLOGY TREATMENT) AMONG PATIENTS WITH STAGE 3 UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
    Zhou, Z.
    Song, J.
    Ouwens, M. J.
    Huhn, M.
    Jiang, H.
    Zhang, Y.
    Dalevi, D.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A416 - A416
  • [6] Body mass index and self-rated health in East Asian countries: Comparison among South Korea, China, Japan, and Taiwan
    Noh, Jin-Won
    Kim, Jinseok
    Yang, Youngmi
    Park, Jumin
    Cheon, Jooyoung
    Kwon, Young Dae
    [J]. PLOS ONE, 2017, 12 (08):
  • [7] Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK1) non-small cell lung cancer (NSCLC) in the United States
    Pan, X.
    Lin, M. M.
    Yin, Y.
    Hou, P.
    Baumann, P.
    Jahanzeb, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Characteristics and treatment patterns of patients with advanced or metastatic non-small cell lung cancer managed with first-line immuno-oncology strategies in Greece: Interim results of a real-world prospective study (IO-HORIZON)
    Linardou, H.
    Charpidou, A.
    Koumarianou, A.
    Mountzios, G.
    Kosmidis, P. A.
    Christodoulou, C.
    Mavroudis, D.
    Christopoulou, A. N.
    Korantzis, I.
    Baka, S.
    Vaslamatzis, M.
    Athanasiadis, I.
    Koutras, A.
    Mauri, D.
    Kotsakis, A.
    Ziogas, D.
    Desiniotis, A.
    Dimitriadis, I.
    Syrigos, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S69 - S70
  • [9] Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA
    Wu, Si Lin
    Zhang, Yao
    Fu, Yi
    Li, Jian
    Wang, Ji Sheng
    [J]. BMJ OPEN, 2022, 12 (07):
  • [10] Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)
    Gutierrez, M. E.
    Norden, A. D.
    Lane, D. C.
    Canavan, B. F.
    Nwokeji, E. D.
    Xu, Y.
    Kaur, S.
    Goldberg, S. L.
    Noh, L.
    Siegartel, L.
    Whittington, J.
    Tuell, K.
    Korytowsky, B.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 436 - 437
12